vs
伯乐实验室（BIO）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
伯乐实验室的季度营收约是ROYAL GOLD INC的1.8倍（$693.2M vs $375.3M），伯乐实验室净利率更高（103.9% vs 24.9%，领先78.9%），ROYAL GOLD INC同比增速更快（85.3% vs 3.9%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs 6.5%）
美国伯乐实验室是深耕生命科学研究与临床诊断领域的专业技术产品开发商及制造商，1952年由加州大学伯克利分校校友施瓦茨夫妇在伯克利创立，总部位于加州赫拉克勒斯，业务网络覆盖全球。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
BIO vs RGLD — 直观对比
营收规模更大
BIO
是对方的1.8倍
$375.3M
营收增速更快
RGLD
高出81.4%
3.9%
净利率更高
BIO
高出78.9%
24.9%
两年增速更快
RGLD
近两年复合增速
6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $693.2M | $375.3M |
| 净利润 | $720.0M | $93.6M |
| 毛利率 | 49.8% | 64.6% |
| 营业利润率 | -17.2% | 56.2% |
| 净利率 | 103.9% | 24.9% |
| 营收同比 | 3.9% | 85.3% |
| 净利润同比 | 200.6% | -12.8% |
| 每股收益（稀释后） | $26.59 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIORGLD
| Q4 25 | $693.2M | $375.3M | ||
| Q3 25 | $653.0M | $252.1M | ||
| Q2 25 | $651.6M | $209.6M | ||
| Q1 25 | $585.4M | $193.4M | ||
| Q4 24 | $667.5M | $202.6M | ||
| Q3 24 | $649.7M | $193.8M | ||
| Q2 24 | $638.5M | $174.1M | ||
| Q1 24 | $610.8M | $148.9M |
净利润BIORGLD
| Q4 25 | $720.0M | $93.6M | ||
| Q3 25 | $-341.9M | $126.8M | ||
| Q2 25 | $317.8M | $132.3M | ||
| Q1 25 | $64.0M | $113.5M | ||
| Q4 24 | $-715.8M | $107.4M | ||
| Q3 24 | $653.2M | $96.2M | ||
| Q2 24 | $-2.2B | $81.2M | ||
| Q1 24 | $383.9M | $47.2M |
毛利率BIORGLD
| Q4 25 | 49.8% | 64.6% | ||
| Q3 25 | 52.6% | 73.6% | ||
| Q2 25 | 53.0% | 72.6% | ||
| Q1 25 | 52.3% | 69.4% | ||
| Q4 24 | 51.2% | 70.3% | ||
| Q3 24 | 54.8% | 66.6% | ||
| Q2 24 | 55.6% | 64.7% | ||
| Q1 24 | 53.4% | 58.4% |
营业利润率BIORGLD
| Q4 25 | -17.2% | 56.2% | ||
| Q3 25 | 10.0% | 64.4% | ||
| Q2 25 | 11.8% | 67.7% | ||
| Q1 25 | 4.0% | 63.6% | ||
| Q4 24 | 8.7% | 65.9% | ||
| Q3 24 | 9.9% | 61.3% | ||
| Q2 24 | 15.9% | 58.6% | ||
| Q1 24 | 7.3% | 50.7% |
净利率BIORGLD
| Q4 25 | 103.9% | 24.9% | ||
| Q3 25 | -52.4% | 50.3% | ||
| Q2 25 | 48.8% | 63.1% | ||
| Q1 25 | 10.9% | 58.7% | ||
| Q4 24 | -107.2% | 53.0% | ||
| Q3 24 | 100.5% | 49.7% | ||
| Q2 24 | -339.2% | 46.6% | ||
| Q1 24 | 62.9% | 31.7% |
每股收益（稀释后）BIORGLD
| Q4 25 | $26.59 | $1.04 | ||
| Q3 25 | $-12.70 | $1.92 | ||
| Q2 25 | $11.67 | $2.01 | ||
| Q1 25 | $2.29 | $1.72 | ||
| Q4 24 | $-25.89 | $1.63 | ||
| Q3 24 | $23.34 | $1.46 | ||
| Q2 24 | $-76.26 | $1.23 | ||
| Q1 24 | $13.45 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | $233.7M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $7.5B | $7.2B |
| 总资产 | $10.6B | $9.5B |
| 负债/权益比越低杠杆越低 | 0.16× | — |
8季度趋势，按日历期对齐
现金及短期投资BIORGLD
| Q4 25 | $1.5B | $233.7M | ||
| Q3 25 | $1.4B | $172.8M | ||
| Q2 25 | $1.4B | $248.2M | ||
| Q1 25 | $1.7B | $240.8M | ||
| Q4 24 | $1.7B | $195.5M | ||
| Q3 24 | $1.6B | $127.9M | ||
| Q2 24 | $1.6B | $74.2M | ||
| Q1 24 | $1.6B | $137.9M |
总债务BIORGLD
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $50.0M | ||
| Q1 24 | — | — |
股东权益BIORGLD
| Q4 25 | $7.5B | $7.2B | ||
| Q3 25 | $6.7B | $3.4B | ||
| Q2 25 | $7.1B | $3.3B | ||
| Q1 25 | $6.7B | $3.2B | ||
| Q4 24 | $6.6B | $3.1B | ||
| Q3 24 | $7.5B | $3.0B | ||
| Q2 24 | $6.8B | $3.0B | ||
| Q1 24 | $9.1B | $2.9B |
总资产BIORGLD
| Q4 25 | $10.6B | $9.5B | ||
| Q3 25 | $9.7B | $4.5B | ||
| Q2 25 | $10.2B | $3.6B | ||
| Q1 25 | $9.5B | $3.5B | ||
| Q4 24 | $9.4B | $3.4B | ||
| Q3 24 | $10.6B | $3.3B | ||
| Q2 24 | $9.7B | $3.3B | ||
| Q1 24 | $12.6B | $3.3B |
负债/权益比BIORGLD
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $164.9M | $241.7M |
| 自由现金流经营现金流 - 资本支出 | $119.1M | — |
| 自由现金流率自由现金流/营收 | 17.2% | — |
| 资本支出强度资本支出/营收 | 6.6% | — |
| 现金转化率经营现金流/净利润 | 0.23× | 2.58× |
| 过去12个月自由现金流最近4个季度 | $374.6M | — |
8季度趋势，按日历期对齐
经营现金流BIORGLD
| Q4 25 | $164.9M | $241.7M | ||
| Q3 25 | $120.9M | $174.0M | ||
| Q2 25 | $116.5M | $152.8M | ||
| Q1 25 | $129.9M | $136.4M | ||
| Q4 24 | $124.2M | $141.1M | ||
| Q3 24 | $163.6M | $136.7M | ||
| Q2 24 | $97.6M | $113.5M | ||
| Q1 24 | $69.8M | $138.3M |
自由现金流BIORGLD
| Q4 25 | $119.1M | — | ||
| Q3 25 | $89.2M | — | ||
| Q2 25 | $70.8M | — | ||
| Q1 25 | $95.5M | — | ||
| Q4 24 | $81.2M | — | ||
| Q3 24 | $123.4M | — | ||
| Q2 24 | $55.4M | — | ||
| Q1 24 | $29.6M | — |
自由现金流率BIORGLD
| Q4 25 | 17.2% | — | ||
| Q3 25 | 13.7% | — | ||
| Q2 25 | 10.9% | — | ||
| Q1 25 | 16.3% | — | ||
| Q4 24 | 12.2% | — | ||
| Q3 24 | 19.0% | — | ||
| Q2 24 | 8.7% | — | ||
| Q1 24 | 4.8% | — |
资本支出强度BIORGLD
| Q4 25 | 6.6% | — | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | 5.9% | — | ||
| Q4 24 | 6.4% | — | ||
| Q3 24 | 6.2% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 6.6% | — |
现金转化率BIORGLD
| Q4 25 | 0.23× | 2.58× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | 0.37× | 1.15× | ||
| Q1 25 | 2.03× | 1.20× | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | 0.25× | 1.42× | ||
| Q2 24 | — | 1.40× | ||
| Q1 24 | 0.18× | 2.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIO
| Clinical Diagnostics | $425.3M | 61% |
| Life Science | $267.9M | 39% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
